Guggenheim Raises Tempus AI (TEM) Price Target to $92
Key Points
- Guggenheim maintained its Buy rating on Tempus AI, Inc. on October 1, 2026, pushing its price target higher from $65.00 to $92.00.
- Guggenheim's $92 price target implies 40.91% upside from Tempus AI, Inc.'s ($TEM) current $65.29 share price.
- Wall Street analysts have issued various updates, including a Buy rating and a $66.00 target from HC Wainwright & Co. on September 11, 2026.
- Tempus AI operates a healthcare technology platform combining diagnostic capabilities with a large repository of clinical data.
Since the rating, $TEM is down 9.4% after 1 week and down 15.9% to date (from the $76.50 close on Oct 1, 2026).
Get Tempus AI text alerts
We text you when insiders, Congress, analysts or big funds move on $TEM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tempus AI, Inc. alert may contain errors. Disclosures
Guggenheim maintained its Buy rating on Tempus AI, Inc. (NASDAQ:TEM) on October 1, 2026, while significantly raising its price target for the healthcare technology company. The update was issued on the same day the stock closed at $76.50. Guggenheim's new target reflects growing confidence in the firm's market position.
TEM
Tempus AI, Inc.
Guggenheim's Call on Tempus AI
Guggenheim kept its Buy rating intact on October 1, 2026, and bumped its price target up from $65.00 to $92.00. Wall Street analysts have actively covered the stock recently. On September 11, 2026, HC Wainwright & Co. maintained a Buy rating and raised its target from $56.00 to $66.00. Earlier in September, Rothschild & Co, UBS, and Goldman Sachs all initiated coverage on the company with Neutral ratings and price targets of $67.00, $70.00, and $75.00, respectively. Overall, the stock holds a consensus buy recommendation from 18 analysts, with a mean target price of $74.94.
Other Institutional Activity in Tempus AI
ARK Investment Management, LLC grew its holdings by 415,048 shares, ending with 10,022,634 shares worth about $644,856,234. BAILLIE GIFFORD & CO cut its stake by 459,284 shares, leaving it with 8,190,133 shares valued at roughly $526,953,127. Softbank Group Corporation kept its position steady with 5,405,406 shares valued at $347,783,802. Sumitomo Mitsui Trust Group, Inc. reduced its holdings by 237,070 shares, finishing with 4,089,029 shares worth about $263,088,110. Amova Asset Management Americas Inc also trimmed its stake by 237,070 shares, holding 4,089,029 shares valued at $263,088,110.
Tempus AI, Inc. Stock Up 0.9%
Shares recently traded around $65.29 as of October 16, 2026, down about 14.7% from the October 1 close. The stock trades below its 50-day moving average of $66.96 but sits above its 200-day moving average of $56.72.
$TEM price target
Tempus AI, Inc. daily closes and this analyst's $92 target. Not advice.
Recent Earnings
Tempus AI reported trailing twelve-month revenue of $1.43 billion and a net margin of negative 17.8%.
Insider Buying and Selling at Tempus AI, Inc.
Insiders have executed multiple transactions ahead of the autumn months. Director David R. Epstein sold 250 shares for $16,388 on September 1, 2026. EVP and Chief Legal Officer Andrew Polovin sold 2,951 shares for $221,325 under a planned trading schedule on September 17, 2026. CEO Eric Paul Lefkofsky sold 250,000 shares valued at $19,366,630 on September 22, 2026. Officer Thomas Edward Schoenherr sold 10,281 shares for $873,885 on September 25, 2026.
About Tempus AI
Tempus AI, Inc. operates a Chicago-based technology platform serving the healthcare sector. The company builds tools that connect a clinician's workspace with laboratory diagnostics and clinical datasets. Its products aim to help medical providers run next-generation sequencing tests and analyze complex patient information efficiently.
Bottom Line
Investors will look toward the company's upcoming earnings release on November 2, 2026, for further operational updates. Guggenheim's updated target highlights changing expectations on Wall Street as the company approaches its next reporting milestone.
Related Filing Alerts
Source: Guggenheim's rating change on $TEM (Oct 1, 2026). Written by software, not financial advice. How we make alerts